Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ADAMTS13

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: ADAMTS13. Displaying page 1 of 1.
    EudraCT Number: 2017-001117-86 Sponsor Protocol Number: 16/0340 Start Date*: 2017-07-25
    Sponsor Name:University College London
    Full Title: A phase IV, prospective, randomised single-blind UK multicentre non-inferiority trial of low-dose versus standard dose rituximab for prevention of relapses in acquired TTP
    Medical condition: Acquired thrombotic thrombocytopenic purpura
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000249-30 Sponsor Protocol Number: 15-HMedIdeS-08 Start Date*: 2016-07-14
    Sponsor Name:Hansa Medical AB
    Full Title: A PHASE II PILOT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS AND PHARMACOKINETICS OF IDES IN ASYMPTOMATIC ANTIBODY-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) PATI...
    Medical condition: Asymptomatic antibody-mediated thrombotic thrombocytopenic purpura (TTP) with low ADAMTS13 activity
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000858-18 Sponsor Protocol Number: 281102 Start Date*: 2017-09-12
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 (rADAMTS13) in the pro...
    Medical condition: severe congenital thrombotic thrombocytopenic purpura (cTTP, Upshaw-Schulman Syndrome [USS], hereditary thrombotic thrombocytopenic purpura [hTTP])
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10043562 Thrombocytopenic purpura, thrombotic LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) AT (Completed) FR (Completed) IT (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003221-19 Sponsor Protocol Number: 281101 Start Date*: 2012-12-17
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: BAX 930 (rADAMTS13) A PHASE 1 PROSPECTIVE, UNCONTROLLED, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS IN HEREDITARY TTP (THROMBOTIC THROMBOCYTOPENIC PU...
    Medical condition: Subjects diagnosed with hereditary thrombotic thrombocytopenic purpura (TTP)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10043562 Thrombocytopenic purpura, thrombotic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001177-31 Sponsor Protocol Number: EFC16521 Start Date*: 2022-08-29
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-m...
    Medical condition: Thrombotic Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001940-36 Sponsor Protocol Number: TAK-755-2001 Start Date*: 2023-02-13
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombo...
    Medical condition: immune-mediated thrombotic thrombocytopenic purpura (iTTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005288-30 Sponsor Protocol Number: 2019/408/HP Start Date*: 2020-12-28
    Sponsor Name:CHU de Rouen
    Full Title: Efficacy of a personalized caplacizumab regimen based on ADAMTS-13 activity monitoring in adult acquired thrombotic thrombocytopenic purpura: A phase II, multicenter non-inferiority single-arm study
    Medical condition: acquired thrombotic thrombocytopenic purpura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001032-11 Sponsor Protocol Number: OMS721-TMA-001 Start Date*: 2014-09-30
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 2, uncontrolled, three-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombo...
    Medical condition: Three forms of thrombotic microangiopathies (TMA): - atypical hemolytic uremic syndrome (aHUS) - hematopoietic stem cell transplant (HSCT)-associated TMA - thrombotic thrombocytopenic purpura (TTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001082-24 Sponsor Protocol Number: ALN-CC5-004 Start Date*: 2017-08-18
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome
    Medical condition: Atypical Hemolytic Uremic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10019515 Hemolytic uremic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-018794-38 Sponsor Protocol Number: RTXTTP2010 Start Date*: 2010-02-23
    Sponsor Name:FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
    Medical condition: THROMBOTIC THROMBOCYTOPENIC PURPURA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037562 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001817-20 Sponsor Protocol Number: NL73805.100.20 Start Date*: 2021-05-07
    Sponsor Name:St. Antonius Hospital Nieuwegein, The Netherlands
    Full Title: Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation
    Medical condition: Thromboembolic, bleeding and vascular complications after transcatheter aortic valve implantation in patients using oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003775-35 Sponsor Protocol Number: SHP655-201 Start Date*: 2019-07-03
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficac...
    Medical condition: acquired thrombotic thrombocytopenic purpura (aTTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005897-28 Sponsor Protocol Number: P060801 Start Date*: 2009-01-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Utilisation du rituximab dans le purpura thrombotique thrombocytopénique autoimmun en association aux échanges plasmatiques
    Medical condition: Purpura Thrombotique Thrombocytopénique autoimmun (PTT).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10043562 PTTA PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002057-11 Sponsor Protocol Number: OMS721-HUS-002 Start Date*: 2017-09-15
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents.
    Medical condition: Atypical Hemolytic Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10019515 Hemolytic uremic syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003348-10 Sponsor Protocol Number: TAK-755-3002 Start Date*: 2020-11-17
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and o...
    Medical condition: congenital Thrombotic thrombocytopenic purpura (TTP)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) ES (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001098-42 Sponsor Protocol Number: ALX0681-C301 Start Date*: 2015-08-27
    Sponsor Name:Ablynx NV
    Full Title: A Phase III double-blind, randomized, parallel group, multicenter placebo-controlled trial to study the efficacy and safety of caplacizumab in patients with acquired thrombotic thrombocytopenic pur...
    Medical condition: Acquired Thrombotic thrombocytopenic purpura
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) ES (Completed) AT (Completed) DE (Completed) HU (Completed) NL (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 21:55:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA